01—Abstract
Summary
Summary of the 10-K filed February 22, 2022. Cited figures are marked; the original filing is the authoritative source.
TransUnion (NYSE: TRU) reported total revenue of $2,960.2 milliona for the year ended December 31, 2021, up from $2,530.6 million in 2020, a year-over-year increase of 17.0%.
Income from continuing operations rose to $370.5 millionb from $305.7 million, an increase of 21.2%. Consolidated Adjusted EBITDA increased to $1,156.9 million from $953.6 million, up 21.3%. The filing attributes 2021 growth to improving macroeconomic conditions in all markets, new product initiatives, and recent acquisitions, while noting COVID-19 remains a risk.
Net income attributable to TransUnion was $1,387.1 millionc, boosted by a $982.5 million after-tax gain on the sale of the Healthcare business, which closed December 17, 2021. The year was dominated by two large acquisitions completed December 1, 2021: Neustar for $3,106.6 million in cash and Sontiq for $642.8 million in cash. Both were funded with debt, and book value of debt rose to $6,365.9 million at year end from $3,454.2 million a year earlier.
Cash and cash equivalents ended the year at $1,842.4 milliond. Subsequent events include a $400 million prepayment of Senior Secured Term Loans on January 31, 2022, and an expected approximately $515 million purchase of Verisk Financial Services in the second quarter of 2022. Investors should note the risk disclosures around the U.S. Consumer Financial Protection Bureau, which has a NORA letter pending and an accrual of $26.5 million, with a reasonable possibility of losses above that amount.
The Ramirez FCRA class litigation has a tentative settlement reached January 24, 2022, expected to be resolved by the end of 2022. Interest rate exposure is material, as essentially all debt is variable-rate, partly hedged by swaps.
02—Key points
Key Highlights
- Total revenue rose 17.0% to $2,960.2 million in 2021 from $2,530.6 million in 2020, with U.S. Markets gross revenue up 18.6% to $1,791.0 million.
- Consolidated Adjusted EBITDA increased 21.3% to $1,156.9 million, with a consolidated Adjusted EBITDA margin of 39.1% versus 37.7% in 2020.
- Net income attributable to TransUnion was $1,387.1 million, including a $982.5 million after-tax gain on the sale of the Healthcare business closed December 17, 2021; income from continuing operations attributable to TransUnion was $355.5 million.
- Acquired Neustar for $3,106.6 million in cash and Sontiq for $642.8 million in cash on December 1, 2021, funded primarily through incremental term loans, lifting total debt to $6,365.9 million.
- Cash and cash equivalents of $1,842.4 million at year end, versus $492.7 million at December 31, 2020, after receiving $1,706.8 million from the Healthcare disposal.
- Pending CFPB enforcement matter with a $26.5 million accrual and a reasonable possibility of losses above that amount; Ramirez FCRA class action reached a tentative settlement on January 24, 2022.
- Subsequent events include a $400 million term loan prepayment on January 31, 2022 and an expected approximately $515 million acquisition of Verisk Financial Services in the second quarter of 2022.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2021filed February 22, 2022Financial Statements
FY2021 against FY2020
| Line item | FY2021FY2020 | Change |
|---|---|---|
| Revenue | $2.96B$2.53B | +17.0% |
| SG&A Expenses | $909.00M$829.70M | +9.6% |
| Operating Expenses | $2.31B$2.03B | +13.7% |
| Operating Income | $651.90M$500.30M | +30.3% |
| Interest Expense | $112.60M$126.20M | −10.8% |
| Net Income | $1.39B$343.20M | +305.1% |
| EPS (Basic) | $7.26$1.81 | +301.1% |
| EPS (Diluted) | $7.20$1.79 | +302.2% |
| Shares Outstanding (Basic) | 191.40M189.90M | +0.8% |
| Shares Outstanding (Diluted) | 193.00M192.20M | +0.4% |
05—Questions
Frequently Asked Questions
How did TransUnion perform financially in 2021?
Revenue grew 17.0% to $2,960.2 million and income from continuing operations rose 21.2% to $370.5 million. Consolidated Adjusted EBITDA increased 21.3% to $1,156.9 million. The filing attributes improvement to macroeconomic recovery in all markets, new product initiatives, and recent acquisitions.
What were the major acquisitions in 2021 and how were they financed?
TransUnion acquired Neustar for $3,106.6 million in cash and Sontiq for $642.8 million in cash, both completed December 1, 2021. Neustar was financed mainly through an incremental Senior Secured Term Loan B-6 of $3,100.0 million, and Sontiq through a $640.0 million Second Lien Term Loan that was fully repaid on December 23, 2021.
How much debt does TransUnion carry and what are the main risks?
Total debt was $6,365.9 million at December 31, 2021, up from $3,454.2 million a year earlier. Essentially all debt is variable-rate, with some exposure hedged by interest rate swaps. The filing also notes a credit rating downgrade by one agency following the Neustar and Sontiq financing.
What is the status of the Healthcare business sale?
The Healthcare business was sold to nThrive, Inc. for $1,705.9 million in cash on December 17, 2021, with a gain on disposal of $982.5 million, net of tax. The filing estimates approximately $352 million of income taxes related to the gain will be paid in April 2022.
What legal and regulatory issues could affect TransUnion?
The CFPB's Enforcement Division has indicated it may pursue litigation over alleged violations of a 2017 Consent Order and Consumer Interactive marketing practices; the company has accrued $26.5 million and is in settlement discussions. In the Ramirez class action, a tentative settlement was reached January 24, 2022, subject to court approval, with resolution expected by the end of 2022.
06—Continue